07:13 AM EDT, 06/25/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Tuesday that high-level results from the phase 3 trial of Imfinzi in early-stage non-small cell lung cancer did not achieve "statistical significance" for the primary endpoint of disease-free survival compared with placebo.

The trial investigated Imfinzi after complete tumor resection in patients whose tumors express PD-L1 on 25% or more tumor cells, said the company.

Imfinzi's safety profile in the trial was consistent with its known safety profile and data from the phase 3 trial will be shared at an upcoming medical meeting, according to the company.

AstraZeneca ( AZN ) said Imfinzi continues to be under clinical trials as a monotherapy and as part of combination therapies in other early-stage lung cancer settings.

Price: 79.63, Change: +0.26, Percent Change: +0.33